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Objective:	To	assess	how	clinical	practice	of	noninvasive	ventila-
tion	has	evolved	in	the	Italian	PICUs.
Design:	National,	multicentre,	retrospective,	observational	cohort.
Setting:	Thirteen	Italian	medical/surgical	PICUs	that	participated	
in	the	Italian	PICU	Network.
Patients:	 Seven	 thousand	 one-hundred	 eleven	 admissions	 of	
children	with	0–16	years	old	admitted	from	January	1,	2011,	to	
December	31,	2012.
Interventions:	None.
Measurements and Main Results:	Cause	of	respiratory	failure,	length	
and	mode	 of	 noninvasive	 ventilation,	 type	 of	 interfaces,	 incidence	
of	 treatment	 failure,	and	outcome	were	recorded.	Data	were	com-
pared	with	an	historical	cohort	of	children	enrolled	along	6	months	
from	November	1,	2006,	 to	April	 30,	2007,	over	 the	 viral	 respira-
tory	season.	Seven	thousand	one-hundred	eleven	PICU	admissions	
were	analyzed,	 and	an	overall	 noninvasive	 ventilation	use	of	8.8%	 
(n	=	630)	was	observed.	Among	children	who	were	admitted	in	the	
PICU	without	mechanical	ventilation	(n	=	3,819),	noninvasive	ven-
tilation	was	used	 in	585	patients	 (15.3%)	with	a	significant	 incre-
ment	among	the	three	study	years	(from	11.6%	in	2006	to	18.2%	
in	 2012).	 In	 the	 endotracheally	 intubated	 group,	 17.2%	 children	
received	noninvasive	ventilation	at	the	end	of	the	weaning	process	
to	avoid	reintubation:	11.9%	in	2006,	15.3%	in	2011,	and	21.6%	in	
2012.	Noninvasive	ventilation	failure	rate	raised	from	10%	in	2006	
to	16.1%	in	2012.
Conclusions:	Noninvasive	ventilation	is	increasingly	and	success-
fully	used	as	first	respiratory	approach	in	several,	but	not	all,	Italian	
PICUs.	The	current	study	shows	that	noninvasive	ventilation	rep-
resents	a	feasible	and	safe	technique	of	ventilatory	assistance	for	
the	treatment	of	mild	acute	respiratory	failure.	Noninvasive	ventila-
tion	was	used	as	primary	mode	of	ventilation	in	children	with	low	
respiratory	tract	infection	(mainly	in	bronchiolitis	and	pneumonia),	
in	acute	on	chronic	respiratory	failure	or	to	prevent	reintubation.	
(Pediatr Crit Care Med	2015;	16:418–427)
Key Words:	 children;	 noninvasive	 ventilation;	 pediatric	 intensive	
care	units;	respiratory	insufficiency;	treatment	failure;	weaning
Noninvasive mechanical ventilation (NIV) is defined as the delivery of positive pressure (continuous and/or intermittent) using an external interface without the 
need for an invasive airway, such as endotracheal intubation or 
tracheostomy. As a general definition, NIV includes both non-
invasive continuous positive airway pressure (CPAP) and non-
invasive intermittent positive pressure ventilation (1). High 
flow nasal cannula (HFNC), available since the last 10 years, is 
considered as a cross over therapy from basic oxygen therapy to 
NIV (2). NIV offers greater flexibility in applying and remov-
ing ventilatory assistance and preserves airway defence mech-
anisms, speech, and swallowing, besides favorable effects on 
gas exchange and significantly fewer complications than inva-
sive mechanical ventilation (MV) via endotracheal tube (3–7). 
However, the success rate of NIV may vary depending upon 
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several factors, including the type of acute respiratory failure 
(ARF), the underlying disease, the timing, and the experience 
of the team (3, 8). Children have a higher risk of respiratory 
failure with a more rapid development of hypoxemia and ARF 
is a common indication for admission in the PICU. This may 
justify an early use of NIV as soon as clinical signs of impend-
ing respiratory failure develop as endotracheal intubation is 
the most important risk factor for nosocomial pneumonia; 
increase the risk of baro/volotrauma and the tube may dam-
age the tracheal mucosa and can results in substantial mor-
bidity and mortality (9–12). NIV in pediatric ARF seems 
conceptually very interesting, but, although it is widely used 
in premature babies, in children up to now reports have been 
scarce; retrospective studies and case series represent most of 
the available knowledge (13–16), and only one randomized 
controlled trial has been published (17). The aim of this study 
was to assess, along 5 years, the following aspects related to 
NIV use: the current clinical diffusion of NIV in PICUs, the 
primary indication for its use, and the outcome of children 
with ARF treated with NIV.
MATERIALS AND METHODS
All the 21 general M/S Italian PICUs were invited to participate 
in the study. The study is a retrospective analysis of an ongoing 
national registry on PICUs patients and was conducted along 
two years from January 1, 2011, to December 31, 2012. Data 
were compared with an historical cohort of children, which 
were enrolled along 6 months from November 1, 2006, to 
April 30, 2007, over the viral respiratory season. The 2006 data 
were partially published in a previous study on endotracheal 
mechanical ventilated children admitted in PICU (18). Vittore 
Buzzi Children’s Hospital was the promoter and the coordina-
tor of the survey. The study was approved by the Ethics Com-
mittee of all the participating centers.
All children, aged from newborn (including premature 
from 35 weeks of gestational age) up to 16 years, consecutively 
admitted to PICUs were enrolled in the study. The following 
information were recorded for each patient: age, gender, type 
of admission (medical, surgical, and trauma), origin (operat-
ing room, Emergency Department, ward, other hospital, and 
hemodynamic room), reason of admission, underlying chronic 
disease (defined as any medical condition that can be reason-
ably expected to last at least 12 mo, unless death intervenes, and 
to involve either one or more different organ systems) (19), 
immunodeficiency (classified as congenital, chemotherapy, 
HIV infection, steroid therapy, and transplant), PICU length of 
stay (LOS), and PICU mortality. A severity score, the Pediatric 
Index of Mortality 2 (PIM2), previously validated in the 
Italian PICUs (20), was recorded on admission. Each patient, 
on admission, was classified as on spontaneous breathing 
(SB) or on MV either endotracheally intubated (ETI) or NIV. 
Subsequently, each change of ventilation pattern was recorded: 
from SB to MV, from MV to SB, from NIV to ETI, and from 
ETI to NIV; four groups were defined as follows: ETI only, NIV 
only, ETI + NIV (weaning), and NIV + ETI (NIV failure). ARF 
was defined as any form of respiratory insufficiency requiring 
respiratory support according to clinical judgment and venti-
latory support was started by the attending physician based on 
local protocol. ARF was classified as hypoxemic (SaO
2
 < 90% 
on face mask or oxygen hood), respiratory distress (increase of 
respiratory rate and increased work of breathing), or hyper-
capnic (either PCO
2
 > 60 mm Hg or pH < 7.2). Reason for 
admission was classified as follows: respiratory failure, surgical, 
trauma, altered consciousness/seizures, cardiovascular failure, 
sepsis-related diagnosis, metabolic disorders and dehydration, 
prematurity, and others causes.
NIV use after endotracheal extubation was decided either as 
a preventive treatment or to treat an incipient weaning failure. 
Blood gas analysis either arterial or capillary (if available) was 
recorded at the beginning of ventilation. Ventilation modes 
were classified as follows: CPAP, pressure support ventilation, 
assisted pressure control ventilation (A-PCV). The number of 
days with each ventilatory treatment and the type of interface 
were recorded. Finally, the rate of NIV failure and complica-
tions were recorded.
For the intention-to-treat analysis in the comparison 
between ETI and NIV intervention after admission, a sub-
population of the whole cohort was selected by identifying 
and excluding from the analysis those children admitted in 
PICU already intubated or in NIV, with a contraindication to 
NIV (ie, altered consciousness and cardiovascular failure) as 
described by Muñoz-Bonet et al (21) and admitted for end-of-
life treatment (i.e., palliative admission).
Statistical Analysis
Excel (Excel; Microsoft Corporation, Redmond, WA) and Statis-
tical Package for the Social Sciences (version 13.0.; SPSS, Chicago, 
IL) were used for data management and analysis. To describe 
the study population, data were expressed as frequencies and 
percentages for categorical variables and either as median with 
interquartile range or mean ± sd for continuous variables as 
appropriate. The distribution of the data was not normal for any 
of the continuous variables (age, LOS, PIM, and length of ven-
tilation) and a nonparametric test was used (Kruskal–Wallis H 
and Mann–Whitney U test) to test differences among the study 
years and between the ventilation categories. For categorical 
variables, comparisons were performed using the χ2 text.
RESULTS
Thirteen over 21 general M/S Italian PICUs (61.9%) accepted 
to participate in the study. Six units were located in Children’s 
Hospital. None of the hospitals had a low-intensive or post-
anesthesia unit; therefore, most of the units admitted not only 
acute critical children but also patients for postoperative care 
and medical therapies, such as vasopressor support and renal 
replacement in hematologic/oncologic patients.
In all, 7,111 admissions were recorded and analyzed: 1,370 
in 2006, 3,000 in 2011, and 2,741 in 2012 (Fig. 1). There was no 
significant difference for gender, among the study years, with 
a prevalence of male. In 2006, the mean age was lower than in 
2011 and 2012 (p < 0.001). The main reasons for admission 
were surgery (35.3%, 35.8%, and 38.5%, respectively, in 2006, 
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2011, and 2012) and respiratory failure (30.5, 23.2, and 25.6), 
whereas trauma patients represented a small part of children. 
Comorbidity was significantly higher in 2006 than in 2011 and 
2012 (42.5 vs 32.3 vs 37.8, respectively; p < 0.001) (Table 1).
Overall, almost half of the children admitted in PICU (49.1%) 
did not receive any kind of MV without significant changes 
from 2006 to 2012. In this time period, the increase of MV after 
admission was statistically significant (p < 0.001) and not dif-
ferent when comparing ETI versus NIV (p = 0.098). Severity on 
admission and LOS were not different during the study period as 
well as mortality, which was 4.2% in the overall cohort (Table 1).
To assess the prevalence of ventilation, children admitted 
in PICU already intubated or in NIV, children with contrain-
dication for NIV, and children admitted for end-of-life care 
(n = 3,292) were then excluded from the analysis (Fig. 1). The 
remaining 3,819 patients were subdivided for ventilatory sup-
port received during PICU admission and stay: 2,740 (71.7%) 
did not receive any MV, whereas 494 (12.9%) were intubated 
and 585 (15.3%) had NIV (Table 2).
Children treated with NIV were significantly younger 
than those in SB and those intubated (5.9, 10.5, and 11.6 mo, 
respectively; p < 0.001) and were admitted mainly for respi-
ratory failure (74.9%). Severity on admission indicated as 
risk of death, was 3.6% in NIV group, and 5.8% in intubated 
group (p = 0.11), whereas mortality was significantly higher in 
ETI children (6.9%) than in those who received NIV (1.5%) 
and those in SB (1.0%). Comorbid children were significantly 
more in the intubated group 
(48.8%) as well as children 
with immunodeficiency 
(6.5%).
The use of NIV increased 
significantly along the 3 years 
of study: 11.6% of children 
received NIV in 2006, 14.3% 
in 2011, and 18.2% in 2012 
(p < 0.001). Among age cat-
egories, NIV use ranged from 
2.7% among adolescent to 
34.5% among infants. Figure 2 
shows the specific NIV rate for 
patient typology (respiratory, 
surgical, and others), whereas 
Figure 3 shows NIV use and 
failure rate for admission 
diagnosis. Among acute on 
chronic, 29 children (32.5%) 
had a chronic respiratory dis-
ease and 59 (67.5%) had a neu-
romuscular disease.
Three hundred ninety-six 
noninvasively ventilated chil-
dren (67.7%) started ventila-
tion within the first hour of 
PICU stay, whereas 32.3% later 
on. NIV was used, on average, 
for 3.56 days in 2006 (range, 0–77), 3.45 days in 2011 (range, 
0–70), and 4.0 days in 2012 (range 0–64). CPAP was the most 
used NIV modality in infant and preschool children in all the 
study years, and the helmet was the most used way to deliver 
CPAP (67.1%). Pressure support ventilation/BiLevel and 
A-PCV modalities increased during the study years and were 
used mainly in school children and adolescent through a nasal 
(46.4%) or a facial (53.6%) mask. Figure 4, A and B shows 
NIV modalities and interfaces, respectively, used divided for 
age categories.
Eighty-five children (17.2%) in the ETI group received NIV 
at the end of the weaning process to avoid reintubation: 11 in 
2006 (11.9%), 31 in 2011 (15.3%), and 43 in 2012 (21.6%). In 
the same way, among children who received NIV as first choice 
of ventilation, 79 children (13.5%) failed a NIV trial and needed 
ETI: 8 children in 2006 (10%), 28 children in 2011 (11.7%), and 
43 in 2012 (16.1%). The lowest failure rate was recorded among 
adolescent (n = 1; 6.2%) and the highest among newborn 
(n = 21; 13.4%). Reasons for NIV failure were hypoxia (n = 28; 
35.4%), hypercapnia (n = 15, 19.0%), or both (n = 18; 22.8%). 
Seventeen children (21.5%) failed NIV due to agitation, all 
in combination with hypoxia or hypercapnia, whereas only 
7 (8.9%) failed for intolerance. Fourteen children who failed 
NIV trial (17.7%) had a difficult cough reflex. Sedation during 
NIV was used in 46 children (7.9%), mainly with midazolam. 
Table 3 shows the cumulative NIV rate, rate of NIV failure, and 
NIV contraindication divided for each center.
Figure 1. Diagram of children distribution for year of study and mode of ventilatory support. MV = mechanical 
ventilation, ETI = endotracheally intubated, NIV = noninvasive ventilation.
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DISCUSSION
Despite a general consensus on the value of NIV in adult patients 
with exacerbation of chronic obstructive pulmonary disease 
and cardiogenic pulmonary edema (20), although NIV use in 
preterm and term neonates is consolidated and is increasing in 
infants with ARF (3, 8, 9, 12, 23–25), noninvasive ventilatory 
support in children is still considered only as a “promising 
therapy” (26). Well-designed, controlled studies on NIV are 
still lacking in pediatric ARF (14), and there are no generally 
accepted guidelines on the use of this technique. To our best 
knowledge, this is the largest multicentre cohort of infants and 
children with ARF treated by noninvasive respiratory support. 
TAbLE 1. Characteristic of Children Enrolled in the Three Different Study Years
Variables
Study Year
p2006 n = 1,370 (3,19) 2011 n = 3,000 (2,42) 2012 n = 2,741 (5,38)
Gender 0.617
  Male 820 (59.9) 1,760 (58.7) 1,597 (58.3)
  Female 550 (40.1) 1,240 (41.3) 1,144 (41.7)
Age, mo, median (IQR, 25–75) 13.2 (2.3–50.2) 10.7 (0.7–54.9) 17.4 (2.5–66.5) < 0.001
 Class of age < 0.001
   Neonates (0–30 d) 219 (16.0) 800 (26.7) 498 (18.2)
   Infants (1–12 mo) 439 (32.0) 753 (25.1) 717 (26.2)
   Preschool (1–5 yr) 468 (34.2) 834 (27.8) 888 (32.4)
   School (6–12 yr) 188 (13.7) 447 (14.9) 454 (16.6)
   Adolescent (13–16 yr) 56 (4.1) 166 (5.5) 184 (6.7)
Reasons of admission < 0.001
  Surgery 483 (35.3) 1,073 (35.8) 1,055 (38.5)
  Trauma 50 (3.6) 157 (5.2) 120 (4.4)
  Medical 837 (61,1) 1,734 (59,0) 1,566 (57,1)
   Respiratory 418 (30.5) 697 (23.2) 703 (25.6)
   Altered consciousness 162 (11.8) 286 (9.5) 254 (9.3)
   Cardiovascular failure 66 (4.8) 142 (4.7) 142 (5.2)
   Sepsis-related diagnosis 71 (5.2)* 60 (2.0) 36 (1.3)
   Metabolic disorders: dehydration 37 (2.7) 63 (2.1) 73 (2.7)
   Prematurity 16 (1.2)* 213 (7.1) 114 (4.2)
   Others 67 (4.9)* 309 (10.3) 244 (8.9)
Comorbidity 582 (42.5) 970 (32.3) 1,037 (37.8) < 0.001
Immunodeficiency 36 (2.6) 112 (3.7) 110 (4.0) 0.075
First ventilation < 0.001
   Never 678 (49.5) 1,547 (51.6) 1,266 (46.2)
   Before PICU 490 (35.8) 904 (30.1) 903 (32.9)
 Endotracheally intubated 117 (8.5) 293 (9.8) 283 (10.3)
 Noninvasive ventilation 85 (6.2) 256 (8.5) 289 (10.5)
Pediatric Index of Mortality 2 %,  
 median (IQR, 25–75)
1.1 (0.5–3.9) 1.1 (0.4–3.5) 1.1 (0.4–3.7) 0.141
Length of stay, d, median (IQR, 25–75) 2.0 (1.0–6.0) 3.0 (1.0–7.0) 3.0 (1.0–7.0) 0.067
Mortality % 58 (4.2) 124 (4.1) 119 (4.3) 0.926
IQR	=	interquartile	range.
Data	are	expressed	as	n	(%).
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Indeed, a recent review on NIV use in PICU (27) showed that 
data in children originate mainly from single-center experience.
The main result of the study is that NIV use is significantly 
increasing. This happens independently from children age (all 
age categories increase NIV use) and in almost all kind of rea-
son of respiratory failure: acute due to low respiratory tract 
infection, to prevent reintubation after a surgical procedure, or 
in acute on chronic respiratory failure. The increasing use of 
TAbLE 2. Characteristic of Children Admitted in PICU Without Ventilation
Variables
Ventilation
p
None  
( n = 2,740)
Endotracheally Intubated 
(n = 494)
Noninvasive Ventilation  
(n = 585)
Overall 
(n = 3,819)
Gender 0.834
  Male 1,622 (59.2) 294 (59.5) 339 (57.9) 2,255 (59.0)
  Female 1,118 (40.8) 200 (40.5) 246 (42.1) 1,564 (41.0)
Age, mo, median  
 (IQR, 25–75)
10.5 (1.3–50.4) 11.6 (1.9–52.7) 5.9 (0.9–30.1) 9.6 (1.3–47.0) < 0.001
 Class of age 0.001
   Neonates 631 (23.0) 94 (19.0) 156 (26.7) 881 (23.1)
   Infants 789 (28.8) 157 (31.8) 202 (34.5) 1,148 (30.1)
   Preschool 829 (30.3) 156 (31.6) 155 (26.5) 1,140 (29.9)
   School 346 (12.6) 65 (13.2) 56 (9.6) 467 (12.2)
   Adolescent 145 (5.3) 22 (4.5) 16 (2.7) 183 (4.8)
Reason of admission < 0.001
  Respiratory 496 (18.1) 242 (49.0)* 438 (74.9) 1,176 (30.8)
  Surgery 1,402 (51.2) 135 (27.3)* 48 (8.2) 1,585 (41.5)
  Other causes 842 (30.7) 117 (23.7)* 99 (16.9) 1,058 (27.7)
  Sepsis-related diagnosis 99 (3.6) 23 (4.7) 13 (2.2) 135 (3.5)
  Metabolic disorders: 
dehydration
121 (4.4) 18 (3.6)* 7 (1.2) 146 (3.8)
  Prematurity 185 (6.8) 13 (2.6)* 57 (9.7) 255 (6.7)
  Others 437 (15.9) 63 (12.8)* 22 (3.8) 522 (13.7)
Comorbidity 855 (31.2) 241 (48.8) 204 (34.9) 1,300 (34.0) < 0.001
Immunodeficiency 95 (3.5) 32 (6.5) 21 (3.6) 148 (3.9) 0.006
Pediatric Index of Mortality  
2 %, median (IQR, 
25–75)
0.4 (0.2–1.1) 1.5 (0.6–5.0) 1.3 (0.7–3.7) 0.6 (0.2–1.6) < 0.001
Length of stay, d, median  
(IQR, 25–75)
2.0 (1.0–4.0) 8.0 (3.0–15.0) 5.0 (3.0–11.0) 2.0 (1.0–6.0) < 0.001
Mortality % 1.0 (27) 6.9 (34) 1.5 (9) 1.8 (70) < 0.001
Study year* < 0.001
  Overall 2,740 (71.7) 494 (12.9) 585 (15.3) 3,819
  2006 515 (75.0) 92 (13.4) 80 (11.6) 687
  2011 1,224 (73.5) 203 (12.2) 238 (14.3) 1,665
  2012 1,001 (68.2) 199 (13.6) 267 (18.2) 1,467
IQR	=	interquartile	range.
*Row	percentages.
Data	from	the	intention-to-treat	population	expressed	as	n	(%).
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NIV has been demonstrated by single-center experience or in 
single disease series. Essouri et al (28) showed an increase from 
0.45% in 2000 to almost 7% in 2004 of NIV used among the 
total number of patients admitted in their PICU, whereas Ganu 
et al (29) showed an increase in the NIV use in infants admitted 
in PICU for bronchiolitis with 
a 2.8% increase per year over 
a decade. Our data showed an 
increase from 6.2% in 2006 to 
10.5% in 2012. This increment 
is more evident when we ana-
lyze children admitted in PICU 
without an endotracheal tube. 
In this case, the NIV rate jump 
from 13.7% in 2006 to 45.7% 
in 2012. It means that the use 
of NIV is more and more con-
sidered as a first-line treat-
ment in children admitted in 
PICU for ARF. Furthermore, 
an electronic survey recently 
conducted in United States 
among pediatric intensiv-
ist demonstrated that almost 
all the participants (n = 386) 
view favorably NIV use (30).
An increase in use of NIV 
corresponded an increase of 
NIV failure rate (ie, children 
who require endotracheal intubation) although not statis-
tically significant. An overall low failure rate of 13.5% was 
observed in the group of children receiving NIV as a first-
line treatment with a strict inverse correlation between 
experience and failure rate: the highest the number of chil-
dren treated with NIV, the 
lowest the number of failure 
as already reported (28). Data 
on failure from other studies 
vary widely: in a physiologi-
cal study on 12 patients with 
hypercapnic ARF, Essouri 
et al (31) reported a lower 
failure rate (8%), whereas 
a higher rate (28%) was 
reported by Yañez et al (17) 
in a multicenter, randomized 
clinical study on 25 patients 
with ARF. In a recent article 
by Mayordomo-Colunga 
et al (32), tracheal intuba-
tion occurred in 15.5% of 
children with ARF in whom 
NIV was used as first-line 
treatment. In a retrospective 
clinical study on 27 infants 
with severe bronchiolitis, 
Javouhey et al (15) reported 
a failure rate of 52%, whereas 
Munoz-Bonet et al (21) and 
Lum et al (33) reported a fail-
ure rate of 19.1% and 20.1%, 
Figure 2. Comparison of endotracheally intubated (ETI) and noninvasive ventilation (NIV) use along the three 
study years (data from the intention-to-treat population).
Figure 3. Reason of noninvasive ventilation (NIV) use and related failure rate along the three study years (data from 
the intention-to-treat population). Children with bronchiolitis (failure in brackets) n = 117 (9); pneumonia n = 114 (20); 
postoperative n = 88 (18); acute on chronic n = 86 (14); acute lung injury (ALI)/acute respiratory distress syndrome 
(ARDS) n = 48 (21); and asthma n = 30 (0). Solid bars refer to NIV use and dotted lines denote NIV failure.
Copyright © 2015 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
Unauthorized reproduction of this article is prohibited
Copyright © 2015 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
Unauthorized reproduction of this article is prohibited
Wolfler et al
424 www.pccmjournal.org	 June	2015	•	Volume	16	•	Number	5
both in single unit prospective study. All these above- 
mentioned studies do suggest that type and severity of acute 
illness, younger age, underlying chronic disease, and toler-
ance to the interface were the most important risk factors 
for NIV failure in children with ARF. In our series, failure 
rate was slightly lower in healthy than in comorbid chil-
dren (12.5% vs 15.2%, respectively). Among healthy ones, 
we had a lower mean age (almost all children were newborn 
or infant) and a more rapid 
deterioration of clinical 
condition with less time on 
NIV. The highest failure rate 
(67.8%) was observed among 
children admitted with acute 
respiratory distress syndrome 
(ARDS), the most severe 
form of ARF and for some 
authors a possible contra-
indication to NIV. The only 
two studies reporting ARDS 
failure rate were published 
by Essouri et al (28) (22% 
of success for ARDS in his 
series) and by Muñoz-Bonet 
et al (50% of success) (21). In 
our series, most of the chil-
dren with ARDS had comor-
bidity, mainly hematological 
malignancies, and NIV was 
started to avoid endotracheal 
intubation, which is strongly 
suggested due to immunode-
ficiency and side effects.
Few children received 
sedation in our series, just 
one patient failed NIV trial 
exclusively for intolerance 
and agitation, whereas others 
failed for hypoxia with agita-
tion. The need of oxygen is 
a reason for agitation; there-
fore, it is most of the time a 
sign of a not corrected respi-
ratory distress than a real dis-
comfort for the interface used 
(16). Furthermore, the use of 
helmet, which represents the 
highest percentage of chil-
dren with NIV in our cohort, 
is generally better tolerated 
than the use of nasal or facial 
mask and might explain the 
low sedation rate.
Interestingly, 30 children 
with asthma were successfully 
treated with NIV without com-
plications or side effects. This technique did not have already 
an evidence base efficacy for asthma, and there is only one ran-
domized observational trial that has described a positive effect 
of peep use through NIV in children with severe asthma (34). 
Nevertheless, our observational data confirm that before endo-
tracheal intubation, it is likely to try a NIV trial.
Most patients were ventilated with pressure-targeted 
respiratory devices. CPAP by nasal mask or helmet was 
Figure 4. A, Noninvasive ventilation use (A) for class of age and for technique along the three study years 
(data from the intention-to-treat population). b, Interfaces use for class of age along the three study years. 
PSV = pressure support ventilation, A-PCV = assisted pressure control ventilation, CPAP = continuous positive 
airway pressure.
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considered as a first-line noninvasive respiratory treatment 
in infants and children with mild to moderate ARF. CPAP 
was administered mainly by high free-flow systems, which 
incorporates a blender, a flow-meter, and an underwater 
positive end-expiratory pressure valve (bubble CPAP) or by 
Infant Flow Systems that converts kinetic energy from a jet 
of fresh gas. The use of pediatric helmet was significantly 
increased between 2006 and 2012, confirming the efficacy 
and good tolerance in children for this relatively new inter-
face, as recently shown by Chidini et al (35, 36). The use of 
A-PCV mode increased significantly in 2012 as the num-
ber of children with neurological/neuromuscular disease 
admitted in PICUs was higher. In these children, nasal or 
oronasal masks were mainly used either with or without 
intentional leaks.
Some authors reported that for specific comorbidities, 
such as neuromuscular and immunocompromised patients, 
NIV should be the first-line treatment (14). In our popula-
tion, neurological chronic diseases were the most frequent 
comorbidities with the lowest NIV failure rate. Children 
with comorbid were older patients (school age and adoles-
cent) and were affected by the most severe ARF. Among these 
patients, NIV was used both as a first-line treatment and after 
extubation in children considered at high risk for complica-
tions, to prevent reintubation. ETI + NIV was also signifi-
cantly increased from 2006 to 2012 and identify a subgroup 
of children characterized by high PIM2 score at admission, 
elevated incidence of associated chronic underlying disease, 
and prolonged LOS in PICU. Because of the increasing rate 
of children with comorbidities admitted in PICU (37), we 
believe that routine use of NIV should be expanded to pre-
vent postextubation respiratory failure.
The use of HFNC was an available option in the registry 
but at the time of the study (2011) only 5 units were using 
HFNC, whereas in two, the use was limited to pediatric ward 
or emergency department and six introduced its use later on. 
Therefore, the number of children treated with this technique 
was too low to be analyzed.
This study has some limitations. The first is that we did 
not record individual ventilatory setting values (ie, inspira-
tory pressure and positive end-expiratory pressure); there-
fore, we have no data on how patients were actively treated 
for each pathology in each centre. The second is that we did 
not define respiratory failure and criteria for starting with 
ETI or NIV, but each unit decided to start with respiratory 
support following local policy. In this way, we might have 
collected data of children treated with MV in early phase of 
ARF. Routine blood gas sampling was not mandatory, and 
gas analysis was recorded if available. It is a matter of fact 
that in a large amount of children admitted in PICU, arte-
rial blood gas analyses is not measured (38), and therefore it 
is difficult to measure and compare severity of ARF. We did 
not report data because of the small number of patient with 
gas analysis at the beginning of MV and they were mainly 
in the ETI group. Most of the children in the NIV group 
were evaluated on the basis of clinical sign more than with 
blood analysis and the Spo
2
/Fio
2
 ratio might represent a more 
reliable marker for NIV patients for future studies. Finally, 
although NIV is increasing, we still observed large differences 
among units with a wide spectrum of use rate (from 4% to 
39%). Nevertheless, none of the principal investigators of 
the participating center agree to participate to a randomized 
trial between endotracheal intubation and NIV. It is feasible 
to design a study where different starting criteria and differ-
ent NIV interfaces might be compared. We propose in the 
Appendix broad guidelines for NIV use as the results of our 
clinical experience in this technique.
CONCLUSIONS
NIV in children is more than a “promising therapy.” The 
results of the current survey show that NIV is more and 
more used as first respiratory approach in Italian PICUs. 
Bronchiolitis, pneumonia, prevention of postoperative 
respiratory failure, and acute on chronic are the main 
reasons for NIV use, and the ratio of NIV failure varies 
accordingly to the cause of acute respiratory failure. NIV 
appears to be particularly used in children with ARF asso-
ciated with a less severe health status when compared with 
patients receiving invasive MV. CPAP was the most fre-
quently used mode of respiratory assistance particularly in 
younger children and the helmet the more frequently used 
interface. Further randomized, controlled trials in children 
with ARF are recommended to confirm these preliminary 
findings.
TAbLE 3. Cumulative Noninvasive Ventilation 
Use, Failure, and Contraindication 
Distributed for Each Participating Unit
Unit Children Excluded NIV Use NIV Failure
1 10.2 12.6 20.0
2 11.1 11.1 0
3 6.9 20.1 3.4
4 8.5 39.6 10.3
5 11.3 29.0 16.7
6 14.9 9.2 53.6
7 9.7 3.7 0
8 7.3 7.6 33.0
9 18.1 6.5 35.7
10 21.0 4.9 40.0
11 33.3 7.4 37.5
12 18.1 15.4 20.8
13 17.3 18.2 9.5
NIV	=	noninvasive	ventilation.
NIV	use	and	failure	were	calculated	on	those	children	eligible	for	mechanical	
ventilation	(n	=	3,819).	NIV	failure	was	calculated	as	NIV	failure/NIV	use.	
Children	excluded	were	estimated	as	the	ratio	between	children	with	
contraindication	and	the	overall	cohort	of	each	center.
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APPENDIX 1. NIV Guidelines (These Guidelines 
Represents the Experience of the Authors and 
Not the Expression of Larger Consensus)
 1. Centers that start noninvasive ventilation (NIV) should 
have different kind of interfaces: nasal, oronasal, total full-
face, helmet of different size and shape, as well as different 
headgears to fit different age categories and weight. Venti-
lators (ICU or Homecare) with specific algorithm for NIV 
(ie, leak compensation) should be used.
 2.  NIV use should be encouraged when children with mild or 
moderate acute respiratory failure are admitted in the PICU. 
All obstructive and restrictive acute renal failure (ARF; 
bronchiolitis, pneumonia, and lower respiratory tract infec-
tion with bronchospasm) admitted in spontaneous breath-
ing might underwent a NIV trial before get intubated.
 3.  NIV use should be encouraged for children with chronic 
respiratory failure due to muscular weakness (myopathy and 
neuromuscular syndromes) or to skeletal deformities during 
acute exacerbation of lower respiratory tract infection.
 4. Besides gas exchange and peripheral oxygen saturation, other 
signs of ARF should be evaluated and treated to prevent sud-
den deterioration: respiratory rate, heart rate, use of inspira-
tory accessory muscle, and expiratory prolonged time. Early 
use of NIV might correct and prevent worsening of ARF.
 5.  Severe form of ARF might be treated with NIV under strict 
surveillance of potential worsening of gas exchange, with-
out delaying endotracheal intubation.
 6.  Continuous positive airway pressure (CPAP) even with 
high positive end-expiratory pressure value (ie, 8–10 
cmH
2
O) might be used in hypoxemic ARF in all class of 
ages. Helmet is an optimal CPAP interface, which cumu-
lates some advantages in terms of less air leak, high toler-
ance in infant as in older children.
 7.  Pressure support ventilation/BiLevel positive airway pres-
sure might be used in hypoxemic ARF when CPAP is not 
efficient in correcting gas exchange and in hypercapnic 
ARF, when inspiratory pressure is needed to increase tidal 
volume. In this case, the caregiver should choose the opti-
mal interface to reduce as possible air leaks.
 8.  Try to adapt the child to the initial settings and then 
gradually increase the maximal inspiratory pressure 
(8–15 cmH
2
O) and positive end-expiratory pressure (4–8 
cmH
2
O) as tolerated, without major leaks.
 9.  Sedation is not needed in all children receiving NIV, but 
should be considered in particularly intolerant patients. 
Hypoxia should be corrected and excluded because it 
might be a possible cause of agitation. Sedation, when 
needed, should be conducted carefully, with pure hypnotic 
drug without effect central drive, excluding drugs affecting 
strength and muscular tone (especially in neuromuscular 
children with chronic respiratory failure). Drugs of choice 
could be dexdemetomidine or midazolam.
10.  Check for air leaks; avoid excessive strap tension; readjust 
straps as needed; or decrease pressure levels if major leaks.
11. Add a heated humidifier (moisture exchanger should not 
be used to avoid excessive dead space).
12. NIV should not be considered as a spare timing technique, 
but as a less invasive ventilation mode. NIV technique, 
indeed, requires time to choose the best interface for each 
patient, to set the mechanical ventilator with appropriate val-
ues of inspiratory and expiratory pressure, to reduce air leak 
patient face, and finally to verify respiration improvement.
